Henlius and dr. reddy's ink licensing deal for hlx15 (investigational daratumumab biosimilar) expansion in europe and the u.s.

Shanghai , feb. 6, 2025 /prnewswire/ -- shanghai henlius biotech, inc. (2696.hk) today announced it has entered into a license agreement with dr. reddy's laboratories sa, wholly-owned subsidiary of dr. reddy's laboratories ltd., (bse: 500124 | nse: drreddy | nyse: rdy | nseifsc: drreddy, along with its subsidiaries hereafter referred to as "dr. reddy's") for the company's independently developed investigational daratumumab biosimilar hlx15, a recombinant anti-cd38 fully human monoclonal antibody injection.
RDY Ratings Summary
RDY Quant Ranking